Načítá se...
Cost Effectiveness of DCISionRT for Guiding Treatment of Ductal Carcinoma in Situ
The DCISionRT test estimates the risk of an ipsilateral breast event (IBE) in patients with ductal carcinoma in situ (DCIS) as well as the benefit of adjuvant radiation therapy (RT). We determined the cost-effectiveness of DCISionRT using a Markov model simulating 10-year outcomes for 60-year-old wo...
Uloženo v:
| Vydáno v: | JNCI Cancer Spectr |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7083239/ https://ncbi.nlm.nih.gov/pubmed/32211582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkaa004 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|